Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Munich - Delayed Quote EUR

Alnylam Pharmaceuticals Inc (DUL.MU)

Compare

232.30

-1.20

(-0.51%)

At close: February 28 at 5:26:30 PM GMT+1

Q4 2024 Vir Biotechnology Inc Earnings Call

Q4 2024 Vir Biotechnology Inc Earnings Call

Thomson Reuters StreetEvents 3 days ago

VIR

SNY

ALNY
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

CAMBRIDGE, Mass., February 25, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. The Company plans to showcase its R&D progress and platform innovation, including updates on multiple near- and mid-stage potentially transformative therapies that represent blockbuster opportunities as its pipeline rapidly expands across multiple therapeutic areas.

Business Wire 5 days ago

ALNY
Alnylam Pharmaceuticals (ALNY): Among the Oversold Biotech Stocks to Buy Now

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against other oversold biotech stocks to buy now. Biotech Sector Performance and Challenges in 2024: Biotechnology stocks are among the most volatile in the market, […]

Insider Monkey 6 days ago

ALNY
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

Zacks 12 days ago

SNY

REGN

ALNY
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y

ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher product sales.

Zacks 16 days ago

ALNY

REGN
Alnylam Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Alnylam Pharmaceuticals ( NASDAQ:ALNY ) Full Year 2024 Results Key Financial Results Revenue: US$2.25b (up 23% from FY...

Simply Wall St. 16 days ago

ALNY
Alnylam Pharmaceuticals Inc (ALNY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Alnylam Pharmaceuticals Inc (ALNY) reports robust financial performance with a 33% revenue growth and outlines strategic plans for 2025 amidst market challenges.

GuruFocus.com 16 days ago

ALNY
Q4 2024 Alnylam Pharmaceuticals Inc Earnings Call

Q4 2024 Alnylam Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents 16 days ago

ALNY
Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 17 days ago

ALNY
Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of 128.57% and 4.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 17 days ago

ALNY
Alnylam: Q4 Earnings Snapshot

ALNY) on Thursday reported a loss of $83.8 million in its fourth quarter. On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 65 cents. Earnings, adjusted for stock option expense and non-recurring costs, came to 6 cents per share.

Associated Press Finance 17 days ago

ALNY
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

CAMBRIDGE, Mass., February 13, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2024 and reviewed recent business highlights.

Business Wire 17 days ago

ALNY
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints

BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.

Zacks 18 days ago

BIIB

ALNY
ILMN vs. ALNY: Which Stock Is the Better Value Option?

ILMN vs. ALNY: Which Stock Is the Better Value Option?

Zacks 19 days ago

ILMN

ALNY
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?

We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.

Zacks 20 days ago

VRTX

ALNY

BIIB
Ahead of Alnylam (ALNY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

Zacks 20 days ago

ALNY
Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 23 days ago

MRNA

ALNY
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 24 days ago

ALNY

EXEL
Are Medical Stocks Lagging Guardant Health (GH) This Year?

Here is how Guardant Health (GH) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.

Zacks 24 days ago

GH

ALNY
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales

PFE beats fourth-quarter estimates for earnings and sales. It maintains 2025 guidance.

Zacks 26 days ago

PFE

ALNY

Performance Overview

Return	DUL.MU	S&P 500
YTD	+3.57%	+1.24%
1-Year	+59.33%	+17.45%
3-Year	+71.38%	+36.14%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alnylam Pharmaceuticals Inc (DUL.MU)

Q4 2024 Vir Biotechnology Inc Earnings Call

Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

Alnylam Pharmaceuticals (ALNY): Among the Oversold Biotech Stocks to Buy Now

SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y

Alnylam Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Alnylam Pharmaceuticals Inc (ALNY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Q4 2024 Alnylam Pharmaceuticals Inc Earnings Call

Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say

Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates

Alnylam: Q4 Earnings Snapshot

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints

ILMN vs. ALNY: Which Stock Is the Better Value Option?

Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?

Ahead of Alnylam (ALNY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Are Medical Stocks Lagging Guardant Health (GH) This Year?

Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales

Performance Overview